Los Angeles Capital Management
MLYS icon

Los Angeles Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Los Angeles Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$448K Sell
16,600
-30,235
-65% -$830K ﹤0.01% 942
2026
Q1 		$1.27M Buy
46,835
+46,560
+16,931% +$1.37M 0.01% 618
2025
Q4 		$11.3K Buy
+275
New +$11K ﹤0.01% 2040

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Los Angeles Capital Management's MLYS Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Mineralys Therapeutics (MLYS) stake by 65% in Q2 2026, selling an estimated $830K and leaving 16,600 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #942.

Los Angeles Capital Management first reported a position in MLYS in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.27M in Q1 2026. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Los Angeles Capital Management held 16,600 shares of Mineralys Therapeutics worth $448K as of Q2 2026.
  • Los Angeles Capital Management sold 30,235 Mineralys Therapeutics shares in Q2 2026, an estimated $830K.
  • Mineralys Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #942 holding.
  • Los Angeles Capital Management first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Los Angeles Capital Management's Mineralys Therapeutics position peaked at $1.27M in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.